Kinapse Partners with Synova Capital for Continuing Growth

Kinapse is pleased to announce the completion of a significant investment from Synova Capital in which Synova Capital has become a substantial minority shareholder of Kinapse.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

London, UK (PRWEB) September 12, 2012

Kinapse is pleased to announce the completion of a significant investment from Synova Capital in which Synova Capital has become a substantial minority shareholder of Kinapse.

The strategic rationale for the partnership is to continue the rapid growth achieved by Kinapse since its establishment in 2005. Through this partnership, Kinapse anticipates fuelling growth and strengthening its ability to serve clients around the world. Kinapse has ambitious plans to develop both its consulting and outsourcing services, moving into new markets and developing new relationships with clients and partners.

Andy Black, Kinapse Chief Executive Officer, commented. “I am delighted to welcome Philip Shapiro to our Board. I look forward to a partnership in which our organisations combine their respective strengths to fulfil Kinapse’s potential as a leader in life sciences expert services.

“We shall be making a range of investments to further strengthen our business, and I look forward to excellent strategic and operational contributions from Synova’s team. This is certainly an exciting time for our business as we implement our largest contracts to date, strengthen our leadership and expand our operations”.

Nicholas Edwards, Chairman of Kinapse, said "Kinapse has achieved rapid growth since its foundation seven years ago. Our partnership with Synova Capital will enable us to continue this growth. We are pleased that they share our enthusiasm and optimism about the Kinapse business."

About Kinapse
‘Collaborating with our clients to innovate for exceptional results’

Kinapse provides business consulting and outsourcing to life sciences organisations. Its clients include many of the world’s leading pharmaceutical companies, leading biotechnology, specialty pharmaceutical and medical devices companies, government organisations and industry service providers.

Headquartered in the UK, Kinapse has offices in London, Philadelphia and New Delhi with partners based in the Americas, Europe and Asia-Pacific and today deploys over 200 industry experts on its projects. Kinapse blends expertise from its multiple locations to deliver services for clients at highest quality and differentiated value.

The benefits Kinapse brings to its clients include continuous productivity improvement, project cycle time reductions, decreased operating costs and mitigation of quality risks.

Contacts:
Kinapse        
Amanda Swain        
T: +44 (0) 20 8946 7600        
Web site: http://www.kinapse.com     

Synova Capital
Laura Plumbley
T: +44 (0) 20 7491 5705
Web site: http://www.synova-capital.com


Contact

  • Amanda Swain
    Kinapse Ltd
    +44 (0) 208 946 7600
    Email

Attachments